To Top

Our Mission

WE ARE COMMITTED TO DEVELOPING NEXT-GENERATION MULTI-SPECIFICS IMMUNE-ONCOLOGY THERAPIES DESIGNED TO DELIVER EFFECTIVE, PRECISE, AND DURABLE ANTI-TUMOR RESPONSES AND IMPROVE OUTCOMES FOR CANCER PATIENTS

Our Pipeline

Purple Biotech CAPTN-3 pipeline: IM1240 and IM1305, both preclinical, in collaboration with Mount Sinai IM1240 IM1305
Skip to content